A chronic dosing study to elucidate longer duration treatment of exendin 9-39 in patients with post-bariatric hypoglycemia (PBH).
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2016
At a glance
- Drugs Exendin 9 (Primary)
- Indications Hypoglycaemia
- Focus Therapeutic Use
- 07 Dec 2016 New trial record
- 29 Nov 2016 According to an Eiger BioPharmaceuticals media release, company has filed an investigational new drug (IND) application with the FDA.